



Issue date: 26 April 2010

NVM Private Equity (NVM) launches RCC Lifesciences Limited

The team who brought you Manchester-based **DxS**, the companion diagnostics company sold to QIAGEN for £82 million in 2009, is pleased to announce that they have launched RCC Lifesciences Limited. **The company will target development capital opportunities within the UK healthcare sector, primarily the lifesciences and medical devices markets.**

Clive Austin, who led the deal for NVM, comments *“NVM has joined forces with Ron Long and Chris Lyddon to provide initial investment of **£3 million** to target lifesciences companies who need funding and expertise to commercialise their products. We expect many companies at this stage of their development will not have faced this type of challenge before, so will hopefully benefit from the experience and financing that RCC Lifesciences can offer them. As Manchester is currently a UK Centre of Excellence in this market, the city should benefit from further investment into targeted lifesciences and medical devices companies.”*

Healthcare is one of the few markets forecasting growth as spending on services and products increase worldwide. Individual patients are now demanding safer, more effective and convenient forms of treatment and political pressure grows in many countries to improve medical services and facilities. The UK has an excellent track record in lifesciences innovation and NVM believes that RCC is in a prime position to help companies who are seeking support to commercialise their products within this market.

Ron Long, former Chairman of DxS, comments *“The UK has a world class University system which delivers a strong flow of innovation. There is however a constant struggle to obtain the financial resources needed to industrialise and commercial new technology. The NVM team are demonstrating that they have the enterprise to support such companies where capital is scarce. The RCC business model will network industrially experienced technical and commercial people to evaluate new opportunities and then to support the development of new businesses. I am very pleased to be involved in supporting this opportunity.”*

NVM is delighted to announce that DxS has won the BVCA/Real Deals Private Equity 'Deal of the Year' Award 2010.

----- ENDS -----

NVM Private Equity Limited (NVM)

NVM is independently owned with 25 years' experience of investing in UK businesses. Our executives live and work on the ground in regional business communities across the UK. NVM manages over £186 million of funds and is a generalist investor specialising in making equity investments in UK unquoted companies. We are focussed on making equity investments of between £2 million and £10 million.

www.nvm.co.uk

For further information please contact:

NVM / RCC Lifesciences

- Liberty Bollen (PR & Marketing) - 0118 951 7017 – liberty.bollen@nvm.co.uk
- Clive Austin (North) – 0845 272 7023 – clive.austin@nvm.co.uk